Polaryx appoints Dr. Will Charlton as Chief Medical Officer; SOTERIA Phase 2 on track for Q4 2026

Polaryx Therapeutics, Inc.

Dr. Charlton appointed CMO effective Sept 1, 2026; brings 15+ years rare disease/pediatric drug development experience.
Previously SVP Clinical Development at Tyra Biosciences; led Phase 2 rare disease trial; also CMO at Spruce Biosciences.
SOTERIA Phase 2 trial of PLX-200 in CLN2, CLN3, Krabbe, Sandhoff diseases; FDA safe-to-proceed Oct 2025; initiation planned Q4 2026.
Dr. Charlton's background includes roles at 89bio, Ascendis Pharma, Allergan; board-certified pediatric endocrinologist.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.